Zepbound (tirzepatide) and Wegovy (semaglutide 2.4 mg) are both licensed for chronic weight management in the UK, but their costs differ substantially between NHS and private pathways. Whilst NHS prescription charges remain standard (£9.90 in England, free elsewhere), access is highly restricted by NICE criteria and local commissioning decisions. Private prescription costs for both medications typically range from £200 to £320 monthly, with annual expenses reaching £2,400 to £3,800 plus consultation and monitoring fees. Understanding these cost differences, alongside clinical suitability and availability, is essential for patients considering these weight management treatments.

Zepbound vs Wegovy: UK Pricing and Availability

Zepbound (tirzepatide) and Wegovy (semaglutide 2.4 mg) are both medications licensed for chronic weight management in adults with obesity or overweight with weight-related comorbidities. Whilst Wegovy has been available in the UK since 2023, Zepbound received regulatory approval from the Medicines and Healthcare products Regulatory Agency (MHRA) more recently, with availability gradually expanding through 2024.

Both medications are administered as once-weekly subcutaneous injections, but work through different mechanisms. Tirzepatide (Zepbound) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide (Wegovy) acts solely on GLP-1 receptors and has demonstrated cardiovascular risk reduction in clinical trials (SELECT trial), though this specific benefit is not yet part of its UK marketing authorisation.

In terms of UK availability, Wegovy is more widely accessible through both NHS and private prescribing pathways, though supply constraints have periodically affected availability. Zepbound's market entry is more recent, and distribution networks are still developing. Patients seeking either medication should be aware that availability may vary by region and prescriber, with some areas experiencing waiting lists or limited stock. Both medications require ongoing monitoring and are intended as adjuncts to a reduced-calorie diet and increased physical activity, not standalone treatments. The choice between these agents often depends on clinical suitability, prescriber familiarity, and importantly, cost considerations which differ substantially between NHS and private provision.

NHS Prescription Costs for Weight Loss Medications

Under the NHS prescription charging system in England, patients who are not exempt pay a standard prescription charge per item (currently £9.90 as of 2024), regardless of the medication's actual cost. This applies to both Zepbound and Wegovy when prescribed through NHS pathways. Patients in Scotland, Wales, and Northern Ireland benefit from free NHS prescriptions, meaning no out-of-pocket costs for these medications when clinically indicated and approved.

However, access to these weight loss medications on the NHS is highly restricted and governed by strict eligibility criteria. For Wegovy, NICE technology appraisal (TA875) recommends its use only within specialist Tier 3 weight management services for adults with:

• A body mass index (BMI) of ≥35 kg/m² and at least one weight-related comorbidity (such as type 2 diabetes, hypertension, or obstructive sleep apnoea), or

• A BMI of ≥30 kg/m² and at least one weight-related comorbidity in specific circumstances with additional risk factors

Patients must also have demonstrated engagement with intensive lifestyle interventions. Treatment is time-limited (maximum 2 years) and requires assessment at 6 months, with discontinuation if weight loss is less than 5%. Zepbound is not yet widely commissioned across NHS services, and local formulary decisions vary. Many integrated care boards (ICBs) have not yet included tirzepatide for weight management in their approved pathways, meaning NHS access remains extremely limited compared to Wegovy.

For those who do qualify for NHS provision, the actual cost to the health service is substantial, but this is borne by the NHS rather than the individual patient. Waiting times for specialist weight management services can extend to many months, and not all areas have established pathways for prescribing these newer agents.

Private Prescription Costs: Zepbound and Wegovy Compared

For patients pursuing private prescriptions, the cost difference between Zepbound and Wegovy becomes immediately apparent and represents a significant financial consideration. Private costs include both the medication itself and associated consultation fees with prescribing clinicians.

Wegovy private prescription costs in the UK typically range from £200 to £300 per month (as of mid-2024), depending on the dose and supplier. The medication is initiated at a lower dose (0.25 mg weekly) and gradually titrated up to the maintenance dose of 2.4 mg over 16–20 weeks. Initial months may be slightly less expensive due to lower starting doses, but patients should budget for the full maintenance cost. Many private providers offer package deals or subscription models, with total annual costs ranging from £2,400 to £3,600 or more.

Zepbound pricing in the UK private market is still emerging but appears broadly comparable or slightly higher, with monthly costs estimated at £220 to £320 depending on dose strength and provider. Like Wegovy, tirzepatide requires dose escalation, starting from 2.5 mg weekly and potentially increasing in 2.5 mg increments (2.5→5→7.5→10→12.5→15 mg) according to tolerability and response. Higher doses command premium prices. Annual private costs for Zepbound may reach £2,600 to £3,800.

Additional expenses include:

• Initial consultation fees: £50–£200 for assessment and prescription

• Follow-up appointments: £40–£100 per review (typically monthly or quarterly)

• Blood tests and monitoring: £50–£150 for baseline and ongoing investigations

Patients should carefully evaluate the total cost of treatment, which extends beyond the medication alone. Some online prescribing services offer lower consultation fees but may provide less comprehensive clinical oversight. It is essential to ensure any private provider is regulated by the Care Quality Commission (CQC), employs GMC/NMC-registered prescribers, and dispenses through GPhC-registered pharmacies. Patients should only obtain these medications through UK-licensed, regulated channels.

Insurance Coverage and Eligibility Criteria in the UK

Private medical insurance (PMI) coverage for weight loss medications in the UK remains extremely limited, with most insurers explicitly excluding obesity treatments from standard policies. Major providers such as Bupa, AXA Health, Aviva, and Vitality typically classify weight management interventions as lifestyle or cosmetic treatments rather than medical necessities, even when obesity-related comorbidities are present.

Some insurers may provide partial coverage in specific circumstances:

• When obesity is directly causing or significantly exacerbating a covered medical condition (e.g., severe osteoarthritis requiring joint replacement)

• As part of pre-surgical optimisation for bariatric surgery covered under the policy

• Within enhanced or executive-level policies that include preventative health benefits

Patients should review their policy documents carefully and contact their insurer directly to clarify coverage. Even when coverage exists, insurers often impose strict eligibility criteria mirroring or exceeding NHS thresholds, requiring documented evidence of failed conventional weight loss attempts and specialist assessment.

Eligibility criteria for both NHS and private prescribing typically include:

• For NHS: BMI ≥35 kg/m² with comorbidities or ≥30 kg/m² with comorbidities in specific circumstances (per NICE TA875 for Wegovy)

• For private: Generally BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities (aligned with UK marketing authorisations)

• Absence of contraindications (including pregnancy, hypersensitivity to the active substance or excipients)

• Commitment to lifestyle modification programmes

• Regular monitoring for efficacy and adverse effects

Patients should be aware of important safety considerations, including risks of pancreatitis (seek urgent care for severe persistent abdominal pain), gallbladder disease, dehydration, and potential worsening of diabetic retinopathy in those with type 2 diabetes. Any suspected side effects should be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

Patients with type 2 diabetes may find broader insurance coverage, as GLP-1 receptor agonists are established diabetes treatments. However, the higher doses used specifically for weight management (Wegovy and Zepbound) are usually distinguished from diabetes formulations in policy terms. Self-funding remains the predominant route for most UK patients seeking these medications outside NHS pathways.

Cost-Effectiveness: Which Medication Offers Better Value?

Assessing cost-effectiveness requires consideration beyond simple price comparison, incorporating efficacy, safety profile, dosing convenience, and long-term health outcomes. Clinical trial data suggest tirzepatide (Zepbound) may produce greater weight loss than semaglutide (Wegovy)—the SURMOUNT-1 trial demonstrated mean weight reductions of 15–22% with tirzepatide versus 10–15% with semaglutide in the STEP trials. The SURMOUNT-5 trial has provided direct head-to-head comparison between these medications, confirming tirzepatide's superior weight reduction efficacy.

From a health economics perspective, NICE evaluates cost-effectiveness using quality-adjusted life years (QALYs). Wegovy has undergone formal NICE appraisal (TA875) and received conditional recommendation for specialist use, with cost-effectiveness demonstrated in specific patient populations when considering long-term health benefits. Zepbound's NICE technology appraisal status is evolving, though its dual incretin mechanism and superior weight loss data may support favourable cost-effectiveness ratios.

Practical value considerations include:

• Treatment response: Both medications require assessment at 6 months. Per NICE guidance for Wegovy, patients not achieving ≥5% weight loss should discontinue treatment, avoiding unnecessary ongoing costs. Similar principles are likely to apply to Zepbound.

• Adverse effect profile: Gastrointestinal side effects (nausea, vomiting, diarrhoea) are common with both agents and may affect tolerability and adherence, potentially reducing value if treatment is discontinued prematurely.

• Cardiovascular benefits: Wegovy has demonstrated cardiovascular risk reduction in the SELECT trial, though this is not yet part of its UK marketing authorisation. Comparable data for Zepbound are awaited.

For NHS patients, the medication offering better value is largely determined by local commissioning decisions and availability rather than individual choice. For private patients, the modest price difference may be less significant than clinical suitability and prescriber expertise. Patients should discuss their specific circumstances, comorbidities, and treatment goals with qualified healthcare professionals to determine which medication, if either, represents appropriate value given the substantial financial commitment required. Neither medication should be viewed as a permanent solution—successful long-term weight management requires sustained lifestyle modification, and costs must be weighed against alternative interventions including behavioural therapy, dietetic support, and potentially bariatric surgery for eligible patients.

Frequently Asked Questions